Gilead Sciences stock: BofA lifts target for Gilead Sciences stock to USD 164.00
Published on 10/19/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- BofA Securities set a USD 164.00 target on October 12, 2026.
- Gilead Sciences will release third-quarter 2026 results on October 29, 2026.
- Gilead Sciences stock costs EUR 139.77 at Lang & Schwarz on October 19, 2026 at 4:10 p.m. CEST, 0.67 percent above the Xetra close of October 16, 2026.
- Gilead Sciences had a USD 194.3 billion market capitalization on October 19, 2026.
BofA Securities raised its price target for Gilead Sciences from USD 162.00 to USD 164.00 on October 12, 2026, while keeping a Buy rating, according to Investing.com. Against the USD 156.72 Nasdaq quote at 10:22 a.m. ET on October 19, 2026, the target lies 4.65 percent above the price. Gilead Sciences stock was trading at EUR 139.77 at Lang & Schwarz on October 19, 2026 at 4:10 p.m. CEST, 0.67 percent above the Xetra close of October 16, 2026 (EUR 138.84).
Second-quarter growth reached 10.00 percent
Gilead's operating picture provides the foundation for the target discussion. In the second quarter of 2026, base business sales rose 10.00 percent year over year to USD 7.60 billion, according to the Yahoo Finance transcript. HIV sales increased 12.00 percent, and management lifted full-year HIV growth guidance to 9.00 percent to 10.00 percent from 8.00 percent.
Stock stays below the yearly high
The Nasdaq quote of USD 156.72 stood 2.36 percent below the 52-week high of USD 160.51 and 37.46 percent above the 52-week low of USD 114.02 on October 19, 2026. Trading volume was 791,463 shares against an average of 6,038,282 shares. The figures place the session price near the upper end of its annual range, while the euro quotation reflects the separate German trading perspective.
Valuation and October 29 results
Gilead Sciences had a USD 194.3 billion market capitalization and a P/E ratio of minus 58.72 on October 19, 2026. The company announced on October 15, 2026 that it will release third-quarter 2026 results after the market closes on October 29, 2026, with a webcast at 4:30 p.m. ET, according to Yahoo Finance. The date gives investors the next fixed point for testing the growth assumptions behind the analyst target.
Comparison with peers
Gilead Sciences: plus 0.67 percent, P/E minus 58.72, market capitalization USD 194.3 billion
Amgen (Nasdaq, USD): plus 0.14 percent, P/E 26.94, market capitalization USD 234.2 billion
Vertex Pharmaceuticals (Nasdaq, USD): plus 1.05 percent, P/E 29.34, market capitalization USD 128.0 billion
Euro price and Xetra comparison
The Lang & Schwarz quote was EUR 139.77 on October 19, 2026 at 4:10 p.m. CEST, up 0.67 percent versus the Xetra close of October 16, 2026 at EUR 138.84. The Nasdaq quote was USD 156.72 at 10:22 a.m. ET on October 19, 2026.
The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz as of October 19, 2026, 4:10 p.m. CEST: EUR 139.77
- Change versus Xetra close: plus 0.67 percent
- Xetra close October 16, 2026: EUR 138.84
- Market capitalization: USD 194.3 billion (as of October 19, 2026)
- 52-week range: USD 114.02-160.51 (as of October 19, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report Nasdaq Composite.
